Want to see YCBD full AI Analyst Report?
Top Page
cbdMD
(YCBD)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.38
▼(-27.12% Downside)
Action:Reiterated
Date:09/23/26
The score is primarily held down by weak financial performance—ongoing losses and very heavy cash burn—along with a longer-term bearish technical setup (below key moving averages and negative MACD). Earnings call and corporate-event updates provide some upside via accelerating sales, planned OpEx savings, and diversification through the Twinlab deal, but margin pressure, working-capital strain, and regulatory uncertainty keep the overall risk profile elevated.
Positive Factors
Revenue and Wholesale Growth
Broad-based sales growth, especially the faster expansion of wholesale distribution, indicates improving market reach beyond the company’s direct channel. If sustained, greater retail availability can support recurring product volume, diversify customer acquisition, and improve the platform’s ability to scale.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow shows that the business has not yet funded operations internally. Continued cash consumption can limit investment flexibility and increase reliance on financing or existing resources, making execution of growth and cost initiatives more financially sensitive.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Wholesale Growth
Broad-based sales growth, especially the faster expansion of wholesale distribution, indicates improving market reach beyond the company’s direct channel. If sustained, greater retail availability can support recurring product volume, diversify customer acquisition, and improve the platform’s ability to scale.
Read all positive factors
cbdMD (YCBD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.37M
Dividend YieldN/A
Average Volume (3M)682.00K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth10.01%
EPS Growth95.01%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,205,045
10 Day Avg. Volume68,974
30 Day Avg. Volume682,002
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.67
Price to Sales (P/S)0.25
P/FCF Ratio-2.97
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit0.61
Enterprise Value/Ebitda-6.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$28.60M
cbdMD Business Overview & Revenue Model
Company Description
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and...
How the Company Makes Money
cbdMD makes money primarily by selling hemp-derived CBD consumer products to end customers and retail/wholesale accounts. Its core revenue streams include: (1) Direct-to-consumer e-commerce sales through its own online channels, where the company ...
cbdMD Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Dec 18, 2026
Earnings Call Sentiment Neutral
The call presented balanced progress: clear top-line growth drivers (20% quarterly revenue growth, 61% wholesale growth, Oasis momentum, >$0.5M from Bluebird) and operational actions (cost reductions, product launches) that position the company to navigate near-term uncertainty. However, margin compression (gross margin down ~570 bps YoY in the quarter), higher operating losses and working capital build, inventory reserves, state-level restrictions, and material regulatory uncertainty are significant headwinds. Management emphasized deliberate investments and a path to improved adjusted EBITDA and lower cash burn, but tangible risks remain until regulatory clarity and cost savings are fully realized.Positive Updates
Top-line Revenue Growth
Net sales grew 20% year-over-year to $5.6 million in the quarter; revenue for the first 9 months increased 12% to $16.2 million (from $14.5 million).
Negative Updates
Gross Margin Pressure
Gross margin declined to 54.7% in the quarter from 61.5% a year ago (9M gross margin 57.3% vs 63.5% prior year), primarily due to a mix shift toward lower-margin wholesale and higher warehouse labor / repacking costs from state regulation changes.
Read all updates
Q3-2026 Updates
Positive
Negative
Top-line Revenue Growth
Net sales grew 20% year-over-year to $5.6 million in the quarter; revenue for the first 9 months increased 12% to $16.2 million (from $14.5 million).
Read all positive updates
Company Guidance
Management guided to $100K–$150K per month of cash OpEx savings (≈$1.2M–$1.8M annualized) starting in Q4—with most savings expected by quarter end (lease savings ≈$10K/month phased in October, supply‑chain savings beginning in September)—and said the cash breakeven quarterly revenue run‑rate is now in the low‑to‑mid $6M range. That guidance accompanies Q3 net sales of $5.6M (+20% YoY; $16.2M for the first 9 months, +12%), wholesale growth of ~61% now ~30% of sales, Bluebird contributing >$0.5M, gross margin of 54.7% (vs 61.5% prior year), operating expenses of ~$4.2M (+12%), an operating loss of ~$1.1M, an improved adjusted EBITDA loss of ~$507K (vs $624K), incremental inventory reserves (~$187K), a ~$150K DTC headwind from state restrictions, cash of ~$2.1M and working capital of ~$4.7M, and management expects these actions to drive better contribution margins and adjusted EBITDA in the next quarter.cbdMD Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.93M | 19.19M | 19.48M | 24.16M | 35.40M | 44.48M |
| Gross Profit | 11.82M | 11.97M | 10.85M | 13.04M | 20.50M | 28.97M |
| EBITDA | -1.18M | -244.98K | -1.85M | -20.01M | -67.11M | -22.01M |
| Net Income | -2.89M | -2.04M | -3.70M | -22.94M | -70.08M | -23.39M |
Balance Sheet | ||||||
| Total Assets | 13.15M | 10.42M | 10.58M | 16.20M | 40.79M | 124.88M |
| Cash, Cash Equivalents and Short-Term Investments | 2.12M | 2.26M | 2.45M | 1.80M | 7.72M | 27.44M |
| Total Debt | 2.21M | 778.24M | 1.27M | 3.68M | 4.87M | 6.07M |
| Total Liabilities | 4.93M | 3.19M | 8.62M | 7.16M | 9.37M | 21.74M |
| Stockholders Equity | 8.21M | 7.23M | 1.96M | 9.03M | 31.42M | 103.14M |
Cash Flow | ||||||
| Free Cash Flow | -626.00M | -1.64M | -642.81K | -4.60M | -15.66M | -16.44M |
| Operating Cash Flow | -443.93M | -1.45M | -352.79K | -4.30M | -14.97M | -14.09M |
| Investing Cash Flow | -18.18M | -184.17K | -290.01K | 702.45K | -688.68K | -2.55M |
| Financing Cash Flow | -56.21M | 1.45M | 1.30M | -1.32M | -4.04M | 28.23M |
cbdMD Technical Analysis
Negative
0.52
Price Trends
0.49
Negative
0.59
Negative
0.73
Negative
Market Momentum
-0.03
Positive
33.04
Neutral
14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YCBD, the sentiment is Negative. The current price of 0.52 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.49, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.04 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YCBD.
cbdMD Risk Analysis
cbdMD disclosed 37 risk factors in its most recent earnings report. cbdMD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
cbdMD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $300.27M | -18.31 | -1.99% | ― | -0.88% | 76.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $38.89M | -2.77 | -27.42% | ― | -100.00% | 95.90% | |
46 Neutral | $523.17M | -2.15 | -10.95% | ― | 15.93% | 93.85% | |
45 Neutral | $4.37M | -1.27 | -34.25% | ― | 10.01% | 95.01% | |
40 Underperform | $2.60M | -1.13 | -107.40% | ― | -11.91% | -285.26% |
* Healthcare Sector Average
YCBD
cbdMD
0.39
-0.89
-69.61%
TLRY
Tilray
3.54
-13.36
-79.05%
SNDL
SNDL
1.22
-1.26
-50.81%
IMCC
IM Cannabis Corp
1.58
-56.92
-97.30%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.10
-9.15
-74.70%
cbdMD Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
cbdMD to Acquire Twinlab Brands, Expanding Wellness Platform
Positive
Sep 2, 2026
On September 1, 2026, cbdMD entered an asset purchase agreement to acquire operating assets and brands of Twinlab through an assignment for the benefit of creditors process, subject to court approval and closing conditions. Consideration includes ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.